Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

Melanoma Clinical Trial

Official title:

A Randomized, Single-center, Open-label, Single Dose, Two-period, Crossover Study to Investigate the Relative Bioavailability of Binimetinib 3 x15 mg and 45 mg Tablets in Healthy Participants

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05103891
• Other study ID #: W00074CI101_1PF73
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: September 3, 2021
• Est. completion date: November 29, 2021

Study information

• Verified date: November 2021
• Source: Pierre Fabre Medicament
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The current commercially available MEKTOVI® (binimetinib) 15 mg tablets are provided as immediate release film-coated tablets for oral administration. For the treatment of adult patients with unresectable or metastatic melanoma with BRAF V600 mutation, the recommended dosing regimen is 45 mg twice daily (bis in die, BID). No food effect with the commercial formulation of 15 mg was demonstrated.

In order to reduce the patient's burden, a new strength tablet containing 45 mg of binimetinib as active ingredient is being developed. As a result, the number of tablets to be taken by the patients will be reduced from 6 tablets (6 x 15 mg) to 2 tablets (2 x 45 mg) per day. The evaluation of the relative bioavailability of the 45 mg tablet in comparison to three 15 mg tablets intake is therefore required.

Description:

The R formulation is the currently commercially available tablet containing 15 mg of binimetinib as active substance, administered as three tablets for a total of 45 mg binimetinib. The T formulation is the tablet containing 45 mg of binimetinib as active substance in one tablet. Participants will be randomized to one of 2 treatment sequences (RT or TR) containing 2 treatment periods, with at least a 7-day washout between each dose.

The study will consist of a screening period between 21 and 2 days before the first study treatment administration on Period (P) 1 Day (D) 1, 2 treatment periods of 5 days each, and a washout of at least 7 days between P1D1 and P2D1.

Study treatments are given by the oral route in fasted condition. The end-of-study (EOS) visit will be performed 30 (± 3) days after the last study treatment administration or discontinuation.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 14
• Est. completion date: November 29, 2021
• Est. primary completion date: November 29, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Healthy participant.

2. Female participants must be postmenopausal or sterilized.

3. Body mass index (BMI) of = 18.5 to < 30 kg/m2, with body weight = 50 kg and < 100 kg.

4. Vital signs within the following ranges or if out of normal ranges, considered as not clinically significant by the Investigator.

5. Participants must have safety laboratory values within the normal ranges or if out of normal ranges considered as not clinically significant by the Investigator.

Exclusion Criteria:

1. Pregnant or currently breastfeeding women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test.

2. A past medical history of clinically significant ECG abnormalities or a family history (grandparents, parents, and siblings) of prolonged QT interval syndrome.

3. Impaired cardiovascular function.

4. History of fainting spells or orthostatic hypotension episodes.

5. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardize the participant in case of participation in the study.

6. History of autonomic dysfunction or Gilbert syndrome.

7. History or current evidence of Central serous retinopathy (CSR), Retinal vein occlusion (RVO) or ophthalmopathy as assessed by ophthalmologic examination at baseline that would be considered a risk factor for CSR/RVO [e.g., optic disc cupping, visual field defects, intraocular pressure (IOP) > 21 mmHg].

8. Neuromuscular disorders that were associated with elevated CK (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).

9. Smoker or use of tobacco products or products containing nicotine in the last 4 weeks prior to first dosing of study treatment.

10. Malignancy with the following exceptions:

1. Adequately treated basal cell or squamous cell carcinoma of the skin (adequate wound healing is required prior to study entry).

2. Primary malignancy which had been completely resected and was in complete remission for = 5 years.

11. History of retinal degenerative disease.

12. Any vaccination within 4 weeks prior to dosing.

Related Conditions & MeSH terms

• BRAF V600 Mutation
• Melanoma
• Metastatic Melanoma
• Unresectable Melanoma

Intervention

Drug:
• Binimetinib Oral Tablet
two-period, crossover study

Locations

Country	Name	City	State
France	Biotrial	Rennes

Sponsors (2)

Lead Sponsor	Collaborator
Pierre Fabre Medicament	Biotrial

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the plasma concentration-time curve (AUC) from time of administration to last observed plasma concentration (AUClast)		Through study completion, an average of 2 months
Primary	AUC from time of administration to infinity (AUCinf)		Through study completion, an average of 2 months
Primary	Maximum observed plasma concentration (Cmax)		Through study completion, an average of 2 months
Primary	Time to reach Cmax (Tmax)		Through study completion, an average of 2 months
Primary	AUC Test(T) / Reference (R) ratios		Through study completion, an average of 2 months
Secondary	Treatment-emergent adverse events (TEAEs)	Incidence, nature and severity	Through study completion, an average of 2 months
Secondary	Treatment-emergent serious adverse events (treatment-emergent SAEs)	Incidence, nature and severity	Through study completion, an average of 2 months
Secondary	Electrocardiograms	heart rate (HR), PR interval, QRS duration, QRS axis, QT interval, QTcF	Through study completion, an average of 2 months
Secondary	Clinical laboratory parameters	Erythrocytes (red blood cells, RBCs), hematocrit, hemoglobin, platelets; leukocyte count with differential: basophils, eosinophils, lymphocytes, monocytes, neutrophils / absolute neutrophil count; RBC indices: mean corpuscular hemoglobin, mean corpuscular volume, reticulocytes/erythrocytes, ALT, albumin, ALP, AST, bicarbonate, bilirubin (total and indirect), urea, calcium, chloride, CK, creatinine, amylase, lipase, total cholesterol, glucose, lactate dehydrogenase, magnesium, potassium, sodium, total protein, uric acid, blood pregnancy test (hCG), coagulation (aPTT or PT)	Through study completion, an average of 2 months
Secondary	Vital signs	Supine and standing systolic BP, diastolic BP and PR, body temperature	Through study completion, an average of 2 months
Secondary	Opthalmologic examinations	Best corrected visual acuity for distance testing, optical coherence tomography and/or fluorescein angiography, slit lamp examination, IOP and dilated fundoscopy with attention to retinal abnormalities	At the screening and at the end of study